Convalescent Plasma for Outpatients with Covid-19

Abstract

In the Covid-19 Convalescent Plasma in Outpatients (C3PO) trial,¹ Korley et al., members of the Strategies to Innovate Emergency Care Clinical Trials Network (SIREN), administered convalescent plasma to high-risk outpatients within 1 week after the onset of symptoms of Covid-19. It is unclear why the authors selected 1 week instead of a shorter time frame, since it has been shown that the 30-day and 60-day mortality benefits of convalescent plasma have been observed when it is administered within 3 days after diagnosis and that the benefit dissipates after this point.^2,3